Compare IMRX & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMRX | CERS |
|---|---|---|
| Founded | 2008 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.7M | 276.0M |
| IPO Year | 2021 | 1996 |
| Metric | IMRX | CERS |
|---|---|---|
| Price | $4.56 | $2.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.20 | N/A |
| AVG Volume (30 Days) | 1.9M | ★ 2.3M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.75 | 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $1.67 | $1.15 |
| 52 Week High | $10.08 | $3.15 |
| Indicator | IMRX | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 54.46 |
| Support Level | N/A | $1.84 |
| Resistance Level | $5.47 | $2.68 |
| Average True Range (ATR) | 0.54 | 0.18 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 10.71 | 43.12 |
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.